Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japanese Ono Pharmaceutical Transfers Clinical Trial Division to U.S.

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Beginning May 1, Ono Pharmaceuticals will transfer its division for coordination of clinical studies in Japan, the U.S. and Europe, to its Lawrenceville, New Jersey wholly-owned subsidiary. Ono's division for promotion of tie-ups with venture businesses and universities will also move to Ono Pharma USA, the Osaka, Japan-based company announced April 21. The reorganization is aimed at facilitating the company's approval for new drugs in the U.S., and upgrading collaboration on clinical studies in its three key markets. Company public relations head Kinya Morimoto told PharmAsia News Ono has been planning for a number of years to launch the approval process for its drugs in the three markets from the U.S. "We have relaunched Ono Pharma USA as our base for global development," Morimoto said. The approval process lag time in Japan did not factor in Ono's decision to move. Rather, the company has set as first priority doing clinical studies and getting approval for drugs in buyer countries, Morimoto explained. "As our development project unfolds, we plan to shift personnel to the U.S.," he said

You may also be interested in...



Merck Products Give Ono Pharma Renewed Life In Japan

TOKYO - Ono Pharma's drug portfolio is "going from maturity to decline," according to a Bank America Merrill Lynch analyst, but there are signs that in-licensed products from Merck, particularly antiemetic Emend (aprepitant), could bring new life to the company

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

SC068622

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel